Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 0.48 |
| ▸ | DRD3 | P35462 | 7/20 | 0.48 |
| ▸ | DRD4 | P21917 | 6/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13063119 | 0.97 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1KMT2A | |
| SCHEMBL13063127 | 0.88 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL13063379 | 0.86 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL13063129 | 0.85 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1 | |
| SCHEMBL12047501 | 0.82 | DRD2 (0.46) | DRD2DRD3 | |
| SCHEMBL3439811 | 0.80 | DRD2 (0.43) | DRD2DRD3DRD4KMT2A | |
| SCHEMBL3439982 | 0.80 | DRD2 (0.48) | DRD2DRD3DRD4OPRM1SLC6A4 | |
| SCHEMBL12012107 | 0.78 | MAPT (0.52) | KMT2AHSD17B10 | |
| SCHEMBL3439732 | 0.77 | DRD2 (0.52) | DRD2DRD3DRD4OPRM1KMT2A | |
| SCHEMBL12012096 | 0.74 | MEN1 (0.41) | KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8252785-B2 | Aryl sulfonamides as bradykinin-B1-receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-28 | — | — | US | disclosed |
| EP-2402329-A1 | Analgetic phenylsulphonamides | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20110021488-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021488-A1 | New Compounds | ABCG2, ADORA2B, ADORA3 | DRD2 25/4885DRD3 14/4885DRD4 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.